

Quzyttir[™] (cetirizine) – New drug approval

- On October 4, 2019, the <u>FDA approved</u> TerSera Therapeutics' <u>Quzyttir (cetirizine)</u> injection, for the treatment of acute urticaria in adults and children 6 months of age and older.
 - Quzyttir is not recommended in pediatric patients less than 6 years of age with impaired renal or hepatic function.
- Quzyttir is the first FDA approved intravenous (IV) formulation of cetirizine. Oral formulations of
 cetirizine are available generically as prescription as well as well over-the-counter (OTC) (eg, Zyrtec[®]).
 - Prescription oral cetirizine is approved for perennial allergic rhinitis and chronic urticaria.
 - Zyrtec and other OTC products are approved for use to temporarily relieve symptoms due to hay fever or other upper respiratory allergies: runny nose, sneezing, itchy and watery eyes, and itching of the nose or throat.
- The efficacy of Quzyttir was established in a randomized, active-controlled, double-blind, single-dose study in 262 adult patients with acute urticaria. Patients were treated with Quzyttir or <u>diphenhydramine</u> injection. The primary efficacy endpoint was the change from baseline in patient-rated pruritus score assessed 2 hours post treatment. The study was non-inferiority design with the pre-specified noninferiority margin of 0.50 for the difference between treatment groups.
 - The effectiveness of Quzyttir was demonstrated to be non-inferior to the effectiveness of diphenhydramine. The mean change from baseline in patient-rated pruritus score was -1.61 and -1.50 for Quzyttir and diphenhydramine, respectively (adjusted difference: 0.06; 95% CI: -0.28, 0.40).
- The efficacy of Quzyttir for the treatment of acute urticaria down to 6 months of age is based on extrapolation of the efficacy of Quzyttir in adults with acute urticaria and supported by pharmacokinetic data with oral cetirizine hydrochloride in patients 6 months to 17 years of age.
- A warnings and precaution for Quzyttir is somnolence/sedation.
- The most common adverse reactions (< 1%) with Quzyttir use were dysgeusia, headache, paresthesia, presyncope, dyspepsia, feeling hot, and hyperhidrosis.
- The recommended dosage regimen for Quzyttir is once every 24 hours as needed. Quzyttir should be administered as an IV push over a period of 1 to 2 minutes. The recommended dosage is based on age:
 - Adults and adolescents 12 years of age and older: 10 mg
 - Children 6 to 11 years of age: 5 mg or 10 mg depending on symptom severity
 - Children 6 months to 5 years of age: 2.5 mg.
- TerSera Therapeutics' launch plans for Quzyttir are pending. Quzyttir will be available as a 10 mg/mL injection.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.